… FOLFOX6 (mFOLFOX6) or FOLFIRI that they had not … of 18% (two out of 11 patients) in this
phase II trial testing erlotinib in … in patients with advanced solid tumors. Clin Cancer Res 13(…

… In a phase II trial in patients with advanced hepatocellular carcinoma (HCC), the … treatment
for metastatic colon cancer in the RESPECT trial, a randomized phase II trial of mFOLFOX6 …

… Chemotherapy-naive patients with RAS wild-type mCRC, aged ≥20 years, were enrolled
… of modified FOLFOX6 (mFOLFOX6) plus panitumumab as induction therapy. Patients who …

… with previously untreated with unresectable advanced CRC ranges from 25 to 30 months,
when … Patients received intravenously modified FOLFOX7 with aflibercept as induction therapy …

… inhibitor (TKI) erlotinib to bevacizumab as maintenance … In a phase II trial, 153 patients
with KRAS exon 2 WT mCRC … , in a phase 1a/1b trial of patients with advanced CEA-positive…

… clinical benefits of BV in patients with advanced gastric 11 and … in mCRC patients treated
with modified FOLFOX6 plus BV (… This study was a multicenter, single-arm, phase II trial …

… of reference bevacizumab in patients with mCRC. The primary objective of this trial was
to … (XELOX [capecitabine plus oxaliplatin] or modified FOLFOX6 [mFOLFOX6: 5-fluorouracil, …

… high-risk stage II, stage III, and stage IV cases for almost 2 decades. … The modified FOLFOX-6
regimen was used in this study. … in patients with locally advanced (stage III) colon cancer. …

… the two outcomes, while in others, like sarcoma, advanced breast cancer, prostate cancer
and NSCLC, the relationship is less clear 2 , 3 . … Phase II randomized study of vandetanib plus …

… trial, the modified FOLFOX6 regimen did not provide additional efficacy compared with 5-
FU/LV in patients with advanced … ®) include combination erlotinib plus gemcitabine among its …